Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen Stock Rocketed 200% Today

By Joe Tenebruso - Feb 8, 2021 at 5:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is raising the cash it needs to fund its experimental coronavirus vaccine's clinical development program.

What happened

Shares of Ocugen (OCGN 10.45%) tripled on Monday after the biopharmaceutical company said it conducted a stock offering at a substantial premium to its closing price on Friday. 

So what 

Ocugen announced on Tuesday that it struck a deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. Following the announcement, investors were bracing for dilution. Clinical trials can be expensive, and Ocugen ended the third quarter with only $19.3 million in cash reserves. So, it was only a matter of time before the biotech would need to sell stock to obtain the cash it needed to fund Covaxin's development in the U.S.

An upwardly sloping stock chart.

Ocugen's stock price soared on Monday. Image source: Getty Images.

What was surprising, however, was that Ocugen was able to price its shares at $7.65, or roughly 46% higher than the price at which they closed on Friday. Ocugen is expected to raise approximately $23 million via the sale of 3 million shares in a direct offering to institutional investors. The sale is expected to close on Feb. 10. 

Now what

With Ocugen's stock rising far above its direct offering price, investors are signaling their optimism that the company will be able to use its newfound cash to fund Covaxin's clinical trials and eventually gain emergency use authorization for the COVID-19 vaccine candidate in the U.S. If it can do so, Ocugen would receive a 45% share of the drug's U.S. profits. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$2.22 (10.45%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.